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Abstract
Introduction: Ghrelin and cannabinoids stimulate appetite, this effect possibly being mediated by the activation of
hypothalamic AMP-activated protein kinase (AMPK), a key enzyme in appetite and metabolism regulation. The cannabinoid
receptor type 1 (CB1) antagonist rimonabant can block the orexigenic effect of ghrelin. In this study, we have elucidated the
mechanism of the putative ghrelin-cannabinoid interaction.
Methods: The effects of ghrelin and CB1 antagonist rimonabant in wild-type mice, and the effect of ghrelin in CB1-knockout
animals, were studied on food intake, hypothalamic AMPK activity and endogenous cannabinoid content. In patch-clamp
electrophysiology experiments the effect of ghrelin was assessed on the synaptic inputs in parvocellular neurons of the
hypothalamic paraventricular nucleus, with or without the pre-administration of a CB1 antagonist or of cannabinoid
synthesis inhibitors.
Results and Conclusions: Ghrelin did not induce an orexigenic effect in CB1-knockout mice. Correspondingly, both the
genetic lack of CB1 and the pharmacological blockade of CB1 inhibited the effect of ghrelin on AMPK activity. Ghrelin
increased the endocannabinoid content of the hypothalamus in wild-type mice and this effect was abolished by rimonabant
pre-treatment, while no effect was observed in CB1-KO animals. Electrophysiology studies showed that ghrelin can inhibit
the excitatory inputs on the parvocellular neurons of the paraventricular nucleus, and that this effect is abolished by
administration of a CB1 antagonist or an inhibitor of the DAG lipase, the enzyme responsible for 2-AG synthesis. The effect is
also lost in the presence of BAPTA, an intracellular calcium chelator, which inhibits endocannabinoid synthesis in the
recorded parvocellular neuron and therefore blocks the retrograde signaling exerted by endocannabinoids. In summary, an
intact cannabinoid signaling pathway is necessary for the stimulatory effects of ghrelin on AMPK activity and food intake,
and for the inhibitory effect of ghrelin on paraventricular neurons.
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Introduction
Ghrelin is a brain-gut peptide that stimulates appetite and also
has direct effects on the regulation of energy balance in the
periphery [1]. It promotes appetite via effects in the hypothalamic
arcuate and paraventricular (PVN) nuclei, both known to be
involved in appetite regulation [2]. Ghrelin stimulates the
orexigenic neuropeptide Y/agouti-related protein neurons and
inhibits the anorexigenic pro-opiomelanocortin/cocaine- and
amphetamine-regulated transcript neurons, thus ultimately en-
hancing appetite [3,4]. In addition, intranuclear injection of
ghrelin into the PVN, where ghrelin receptor-expressing cells are
present [5], also increases appetite [6]. At least one mediator of the
orexigenic effect of ghrelin is AMP-activated protein kinase
(AMPK) [7,8]. AMPK is a key enzyme regulator of energy
homeostasis both centrally and peripherally [2,9]. Hypothalamic
AMPK is a mediator of several appetite-regulating hormones; it is
inhibited by leptin and a-melanocyte stimulating hormone and
activated by ghrelin and cannabinoids [7,8,10]. A large body of
evidence points to the role of the cannabinoid system in the
hypothalamic neuronal regulation of appetite and body weight:
tetrahydrocannabinol (THC), a plant-derived cannabinoid, and
PLoS ONE | www.plosone.org 1 2008 | Volume 3 | Issue 3 | e1797
the endogenous cannabinoids anandamide (AEA) and 2-arachy-
dinoyl glycerol (2-AG), have been shown to increase food intake
via a specific receptor, CB1 [11–13]. We have recently shown that
CB1-immunoreactive axons densely innervate all feeding-related
nuclei in the hypothalamus, via both excitatory and inhibitory
synapses [14]. CB1 is mainly localized to presynaptic axon
terminals and activated by endocannabinoids synthesized and
released by the postsynaptic neurons, a phenomenon otherwise
known as retrograde signaling [12].
We have recently demonstrated that there is an interaction
between ghrelin and cannabinoid-related actions, as sub-anorectic
doses of rimonabant can inhibit the orexigenic effect of ghrelin
injected focally into the PVN [6]. The corticotropin-releasing
hormone- and thyrotropin-releasing hormone-secreting parvocel-
lular neurons of the PVN are known to have an inhibitory effect
on food intake [4]. In the current study we have hypothesized that
the appetite-inducing effects of ghrelin are mediated by the
endogenous cannabinoid system. We have investigated the
interaction between ghrelin and the cannabinoid systems on the
mechanisms underlying appetite regulation by in vivo studies using
rimonabant, a known antagonist of CB1, and by a genetic
approach using CB1-knockout (CB1-KO) mice; we have also
utilized an in vitro electrophysiological system to study the
interaction of the two systems on parvocellular neurons of the
PVN of mice. We show here that ghrelin does not induce appetite
in CB1-KO mice. Furthermore, while ghrelin stimulates hypo-
thalamic AMPK activity in wild-type mice, it has no effect on
AMPK in CB1-KO or in CB1 antagonist-treated mice. The
electrophysiological studies show that ghrelin can inhibit the
excitatory inputs in the parvocellular neurons of the PVN and that
this effect can be abolished by administration of a CB1 antagonist
or THL, an inhibitor of the 2-AG synthesizing enzyme DAG
lipase. The effect is also lost in the presence of BAPTA, an
intracellular calcium chelator, which inhibits the endocannabinoid
synthesis in the recorded cell and therefore blocks retrograde
signaling exerted by endocannabinoids. Thus, the effect of ghrelin
on hypothalamic AMPK, on neuronal activity in the PVN and
ultimately on appetite, are dependent on CB1, and these data
would be compatible with the existence of a ghrelinRendocanna-
binoidRCB1RAMPKRappetite signaling cascade.
Results
A) Food intake
Central administration of 1 mg ghrelin significantly increased
the 2 h food intake in wild-type (WT) animals (ghrelin vs. control
in WT mice: 1.0260.08 g vs. 0.6260.15 g Kruskal-Wallis test:
n = 5–9, df = 3, overall T = 14.4, overall P = 0.0024; for individual
comparison [Conover-Inman test]: critical t (21 df) = 2.07, ghrelin
vs. control P = 0.0045, Fig. 1A). In contrast, ghrelin had no effect
on food intake in the CB1-KO mice (ghrelin vs. control in CB1-
KO mice: 0.4260.07 g vs. 0.4160.1 g, P = 0.7), suggesting that
the effect of ghrelin on appetite is dependent on CB1.
B) AMPK activity in WT and CB1-KO mice
Both THC and ghrelin significantly increased AMPK activity in
the hypothalamus of WT mice (THC: 197640% of control,
ghrelin: 143.2611% of control, Kruskal-Wallis test: n = 6–14,
df = 4, overall T = 23.64, overall P,0.0001; Conover-Inman test
critical t (45 df) = 2.014, THC vs. control P = 0.001; ghrelin vs.
control P = 0.0038; Fig. 1B), while rimonabant significantly
decreased basal AMPK activity (75.768.4% of control,
P = 0.0245). Rimonabant co-administration with ghrelin inhibited
the stimulatory effect of ghrelin: AMPK activity levels in this group
were similar to the control group (94.766.9% of control), and
significantly lower than that in the animals treated with ghrelin
alone (143.2611% of control, P = 0.0008). In CB1-KO animals,
THC did not modulate hypothalamic AMPK activity (85616% of
control, Fig. 1B), suggesting that the AMPK-stimulating effect of
THC is via CB1. Ghrelin administration also had no effect on
AMPK activity in CB1-KO animals (87.7618.5%, Fig. 1B),
suggesting that the AMPK-stimulating effect of ghrelin is CB1-
dependent.
C) Endocannabinoid content of the hypothalamus
Ghrelin treatment significantly increased the 2-AG content of
the hypothalamus of WT mice (control 25.6762.21 vs. ghrelin
36.661.59 pmol/mg tissue, Student’s unpaired t test, n = 6, df = 9,
t = 3.519, P = 0.0065, Fig. 1C). Rimonabant co-administration
with ghrelin prevented the ghrelin-induced increase in 2-AG levels
(79.8610.2% of control, Kruskal-Wallis test, n = 6–14, df = 3,
overall T = 12.62, overall P = 0.0055; Conover-Inman test critical
t (36 df) = 2.028, P = 0.0015 vs. ghrelin, Fig. 1D). In CB1-KO
mice, ghrelin did not change 2-AG content (control 32.062.6 vs.
ghrelin 32.262.2 pmol/mg, Fig. 1C). Anandamide levels showed
a trend towards an increase following ghrelin treatment in WT
mice (control 15.961.8 vs. ghrelin 19.963.12 fmol/mg, P =
0.052, Fig. 1E), whereas no effect was observed in CB1-KO mice
(control 18.565.6 vs. ghrelin 20.968.7 fmol/mg, Fig. 1E).
Rimonabant treatment did not affect AEA levels, and 1-AG levels
were not influenced by any of the treatments (data not shown).
D) Patch-clamp electrophysiology of parvocellular
neurons in the PVN
Whole cell patch-clamp recordings of the parvocellular neurons of
the PVN were used to characterize the postsynaptic currents and the
modulatory effect of ghrelin. The recorded inward current pulses
were miniature excitatory postsynaptic currents (mEPSCs) as all
pulses were abolished by the extracellularly applied kynurenic acid
(5 mM), a non-selective antagonist of the glutamate receptor (data
not shown). Ghrelin (100 nM) significantly inhibited the mEPSCs of
PVN neurons. Ghrelin decreased the amplitude of the pulses to
86.4662.86% of the control (control 213.8960.87pA, ghrelin
211.9660.62pA; Student’s paired t-test n = 8, df = 7, P = 0.0076),
and the instantaneous frequency to 72.3866.57% of the control
(control 11.6961.67Hz, ghrelin 7.7960.53Hz; Student’s paired t-
test n = 8, df = 7, P = 0.0192). Ghrelin also increased the interevent
interval to 181.6624.1% of the control (control 332679.2 ms,
ghrelin 507671.4 ms; Student’s paired t-test n = 8, df = 7,
P = 0.0003). Ghrelin treatment decreased the event frequency to
60.666.95% of the control (control 4.2660.96Hz, ghrelin
2.2160.26Hz; Student’s paired t-test n = 8, df = 7, P = 0.0320)
(Fig. 2A–B and Fig. 3A–D). The distribution of the normalized
cumulative events also showed changes (Fig. 2C), demonstrating that
ghrelin modified the synaptic excitatory transmission of the
parvocellular neurons of the PVN.
In order to examine the involvement of CB1 in mediating the
effect of ghrelin, the CB1 antagonist AM251 (1 mM) was added to
the extracellular solution and 15 min later ghrelin was adminis-
tered (100 nM). Application of AM251 eliminated the changes
caused by ghrelin, since none of the four parameters analyzed
differed significantly from the values calculated from the record-
ings performed without ghrelin (Fig. 2D–E and Fig. 3A–D).
Amplitude was 9862.09% of the AM251 control recordings
without ghrelin (AM251 216.4761.60pA, AM251+ghrelin
215.8961.80pA), instantaneous frequency was 104.665.72% of
the AM251 control (AM251 9.0461.21Hz, AM251+ghrelin
9.4761.41Hz), interevent interval was 107.8611.98% of the
Ghrelin,Cannabinoids,Appetite
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AM251 control (AM251 372685.9 ms, AM251+ghrelin 3396
54.7 ms), event frequency was 96.469.91% of the AM251 control
(AM251 3.2860.71Hz, AM251+ghrelin 3.3260.64Hz; n = 9).
The cumulative event distribution also showed an attenuation of
the effect of ghrelin (Fig. 2F), indicating that CB1 was involved in
the signal evoked by ghrelin.
In order to determine whether the recorded PVN neurons were
involved in the ghrelin-induced production of endocannabinoids
acting on CB1 of the presynaptic excitatory terminals, BAPTA
was added to the intracellular solution filled into the recording
electrode. The presence of BAPTA in the intracellular solution
abolished the effect of ghrelin (Fig. 2G–H and Fig. 3A–D). None of
the four parameters studied were different in the ghrelin-treated
cells from the BAPTA control readings: average amplitude of the
mEPSCs was 94.9262.91% of the BAPTA control (BAPTA
213.8960.886pA, BAPTA+ghrelin 211.9660.617pA), average
instantaneous frequency was 112.2612.42% of the BAPTA control
(BAPTA 5.1160.399Hz, BAPTA+ghrelin 5.6160.465Hz), intere-
vent interval was 104.3613.85% of the BAPTA control (BAPTA
625.8658.28ms, BAPTA+ghrelin 636.4668.66ms) and event
frequency was 101.6612.64% of the BAPTA control (BAPTA
1.6560.169Hz, BAPTA+ghrelin 1.6460.17Hz; n = 7). The cumu-
lative event distribution showed a reduction in the effect of ghrelin
(Fig. 2I), indicating that calcium signal transduction in the
postsynaptic parvocellular neuron plays an indispensable role in
the effect elicited by ghrelin.
After demonstrating that change in the calcium content of the
postsynaptic cell is involved in the effect of ghrelin, the DAG lipase
Figure 1. The effect of ghrelin and cannabinoids on food intake, hypothalamic AMPK activity and endocannabinoid content. (A)
Cumulative food intake of WT and CB1-KO mice after 2 hours of treatment with icv ghrelin (G) or vehicle (C), n = 5–9 mice/group. (B) Ghrelin and
cannabinoid effects on hypothalamic AMPK activity one hour after intraperitoneal administration of THC, ghrelin, rimonabant (R) or a combination of
rimonabant and ghrelin (R+G) in WT and CB1-KO animals compared to vehicle-treated animals, n = 6–14 mice/group. (C) Hypothalamic 2-AG content
after intraperitoneal treatment with ghrelin in WT and CB1-KO animals, n = 6 mice/group. (D) Hypothalamic 2-AG content in WT animals after ip
treatment with ghrelin and rimonabant compared to vehicle treated animals, n = 6–14 mice/group. (E) Hypothalamic AEA content after ip treatment
with ghrelin in WT and CB1-KO animals. All data shown as mean6SEM, *P,0.05, **P,0.01, ***P,0.001, +P= 0.052.
doi:10.1371/journal.pone.0001797.g001
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inhibitor THL was used to investigate the role of endocannabinoid
synthesis in the mediation of the ghrelin-induced inhibition of the
mEPSCs. Application of THL blocked the effect of ghrelin
(Fig. 2J–L and Fig. 3A–D). The average amplitude of the mEPSCs
was 92.2964.02% of the THL control (THL218.6960.825pA,
THL+ghrelin 217.0460.969pA), the average instantaneous
frequency was 107.469.95% of the THL control (THL
6.2560.851Hz, THL+ghrelin 6.7660.962Hz), the interevent
interval was 104.366.79% of the THL control (THL
562.7695.91 ms, THL+ghrelin 577.86101.0 ms) and the event
frequency was 99.1467.11% of the THL control (THL
2.23960.512Hz, THL+ghrelin 2.23460.572Hz; n = 7).
We performed inter-group analysis on the parameters of
mEPSC (Fig. 3A–D). Amplitudes showed no significant changes
(ghrelin compared to BAPTA+ghrelin, AM251+ghrelin, or
THL+ghrelin, Newman-Keuls test). The other three parameters
(instantaneous frequency, interevent interval and event frequen-
cies), however, exhibited significant differences in the ghrelin vs.
BAPTA+ghrelin, the ghrelin vs. AM251+ghrelin and the ghrelin
vs. THL+ghrelin analyses but not in the BAPTA+ghrelin vs.
AM251+ghrelin, the BAPTA+ghrelin vs. THL+ghrelin and the
AM251+ghrelin vs. THL+ghrelin analyses, suggesting that for
these parameters the CB1 receptor antagonist, the 2-AG synthesis
inhibitor and the intracellular Ca2+-chelator inhibited the effects
exerted by ghrelin (Instantaneous frequency ANOVA: P = 0.0090,
F = 5.003; Newman-Keuls test: ghrelin vs BAPTA+ghrelin
P = 0.023, ghrelin vs. AM251+ghrelin P = 0.031, ghrelin vs.
THL+ghrelin P = 0.020. Interevent interval ANOVA: P =
0.0064, F = 5.424; Newman-Keuls test: ghrelin vs BAPTA+ghrelin
P = 0.017, ghrelin vs. AM251+ghrelin P = 0.0073, ghrelin vs.
THL+ghrelin P = 0.012. Event frequency ANOVA: P = 0.0052,
F = 5.675; Newman-Keuls test: ghrelin vs BAPTA+ghrelin
P = 0.013, ghrelin vs. AM251+ghrelin P = 0.0082, ghrelin vs.
THL+ghrelin P = 0.0067; df = 30).
Discussion
In this study we have shown that the effect of ghrelin on the
mechanism of appetite regulation is CB1-dependent: (i) ghrelin
and cannabinoids increase hypothalamic AMPK activity and an
intact CB1 receptor is mandatory for these effects; (ii) ghrelin
increases the cannabinoid content of the hypothalamus and
interestingly CB1 is also involved in this effect; (iii) ghrelin inhibits
excitatory synaptic input in the PVN, an effect which can be
abolished by a CB1 antagonist as well as via inhibition of
cannabinoid synthesis with the use of BAPTA, an intracellular
calcium chelator, and with the use of THL, an inhibitor of the 2-
AG synthesizing enzyme DAG lipase; and ultimately (iv) ghrelin
stimulates appetite and an intact CB1 receptor is necessary for this
effect. These data provide evidence that an interaction between
ghrelin and the cannabinoid systems is crucial for the appetite-
inducing effect of ghrelin.
We have previously shown that rimonabant inhibits the
orexigenic effect of ghrelin in the rat when ghrelin is administered
directly into the PVN [6], and more recently chronic administra-
tion of rimonabant was also shown to suppress the orexigenic
effect of the ghrelin-mimetic hexarelin [15]. As rimonabant has
certain CB1 receptor-independent actions [16,17], we used CB1-
KO animals to show that the ghrelin effects involve the CB1
receptor. On the other hand, our rimonabant data in wild-type
animals suggest that the lack of effect of ghrelin in CB1-KO
animals is not due to compensatory mechanisms induced during
embryonic development. Our study conclusively establishes the
critical role of CB1 in mediating the effects of ghrelin on AMPK
and appetite. We have now demonstrated that the orexigenic
effect of ghrelin is absent in CB1-KO mice, substantiating the
involvement of the cannabinoid system in the effects of ghrelin.
Ghrelin’s effects on AMPK, thought to mediate its orexigenic
effects, are now also definitively shown to be CB1-dependent.
Numerous studies have established that AMPK is involved in
appetite regulation [10] and we have reported, for the first time,
that cannabinoids stimulate hypothalamic AMPK activity while
we and others have shown that ghrelin also has similar effect [7,8].
Our present data demonstrate that the effect of ghrelin on
hypothalamic AMPK activity is also CB1-dependent. Ghrelin did
not affect AMPK activity in CB1-KO hypothalamus, and pre-
administration of the CB1 antagonist rimonabant blocked the
stimulatory effect of ghrelin on AMPK activity, indicating that the
ghrelin-AMPK interaction requires an intact cannabinoid signal-
ing system in the hypothalamus. The concordance between the
effects of rimonabant and the findings in CB1-KO animals at the
level of food intake, AMPK activity and cannabinoid content
clearly supports our hypothesis. Therefore, the effect of ghrelin on
both AMPK and appetite is clearly dependent on an intact
cannabinoid pathway.
Based on these data, we suggest the possibility that ghrelin may
activate CB1 by increasing the synthesis of endocannabinoids.
Endogenous hypothalamic cannabinoid levels have been reported
to increase with fasting and to decrease immediately after re-
feeding [11], suggesting that they may play a role in determining
Figure 2. Whole-cell patch clamp recordings of mEPSCs in the
parvocellular neurons of the PVN. Application of ghrelin (100 nM)
in the extracellular solution decreased the amplitude and frequency of
the mEPSCs (Fig. 2A–C). Extracellular administration of the cannabinoid
receptor antagonist AM251 (1 mM), however, blocked the effect of
ghrelin. Both amplitude and frequency changes were attenuated
(Fig. 2D–F). In addition, intracellularly applied BAPTA, an effective
chelator of free calcium, (Fig. 2G–I) and the DAG lipase (DAGL) inhibitor
THL (5 mM) (Fig. 2J–L) also abolished the effect of ghrelin.
doi:10.1371/journal.pone.0001797.g002
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hunger and satiety. The anorexigenic effect of leptin also seems to
be mediated by reduced endocannabinoid levels [18]. In addition,
glucocorticoids have also been shown to influence the endocanna-
binoid content of the hypothalamus and exert an inhibitory effect
on glutamate release onto parvocellular neurons of the PVN via an
increase in the synthesis of endogenous cannabinoids [19,20]. The
implication of the endogenous cannabinoid system on the effects of
the melanocortin system is contradictory, as a-MSH, at doses
which lead to inhibition of food intake, does not inhibit
endocannabinoid levels, although the MC4R receptor antagonist
HS014 has a late stimulatory effect on 2-AG and AEA levels [21].
Furthermore, the appetite stimulatory effect of another MC4R
antagonist, JKC-363, has previously been shown to be attenuated
by CB1 receptor blockade [22]. Similarly, the orexigenic effect of
orexin A/hypocretin 1 is also blocked by rimonabant administra-
tion [23]. The effect of insulin on hypothalamic endocannabinoid
content, at doses which would inhibit food intake, has not been
reported, but insulin at lower doses which lead to inhibition of
hepatic glucose output does not affect hypothalamic endocanna-
binoid content [21]. In this study we have shown that ghrelin also
influences the hypothalamic endocannabinoid content: ghrelin
significantly increased 2-AG content in the hypothalamus of WT
mice, suggesting that the effect of ghrelin involves an increase in 2-
AG synthesis, which then can stimulate CB1. The activated CB1
receptor then leads to an increase in AMPK activity, and we
suggest ultimately an increase in appetite. Ghrelin exerts its
hypothalamic effects via the growth hormone secretagogue
receptor type 1a, which is a Gq-PKC pathway-coupled receptor.
It has recently been suggested that other receptors using this
pathway may also stimulate endocannabinoid synthesis in
neuronal cells [24]. Interestingly, rimonabant administration
blocked the stimulatory effect of ghrelin on 2-AG content and
ghrelin had no effect on cannabinoid content of the hypothalamus
in CB1-KO animals. These data suggest not only that CB1 is
necessary for the effect of ghrelin on AMPK and appetite, but also
that there may be a positive feedback between the CB1 and the
endogenous 2-AG synthesis. This novel finding is compatible with
recent data which showed increased extracellular 2-AG levels in
rat hypothalamus in response to cannabinoid-agonist stimulation
and decreased 2-AG levels after 10 mg/kg ip rimonabant
treatment [25]. In concordance, with our data, 3 mg/kg
rimonabant did not have an effect on extracellular 2-AG and
AEA levels but it antagonized the effect of the CB1 agonist
WIN55,212-2 on the endocannabinoid release. Bequet et al. also
suggest that rimonabant doses up to 10 mg/kg do not affect
hypothalamus tissue content of endocannabinoids. Interestingly in
this study, AEA release was stimulated by 10 mg/kg rimonabant,
suggesting a different regulation and possibly different physiolog-
Figure 3. Changes of various parameters of mEPSCs [(A) amplitude, (B) instantaneous frequency, (C) interevent interval, (D) event
frequency] elicited by ghrelin (as percentage of control), by AM251+ghrelin (as percentage of AM251 alone), BAPTA+ghrelin (as
percentage of BAPTA alone) and THL+ghrelin (as percentage of THL alone) in the parvocellular neurons. Application of ghrelin resulted
in significant changes in all of these parameters whereas administration of AM251, BAPTA or THL eliminated the changes (Fig. 3A–D). All data shown
as mean6SEM, a and b correspond to P,0.05 and P,0.01, respectively, and refer to the comparison of ghrelin vs. control. *P,0.05 and **P,0.01
correspond to the comparison between ghrelin vs. AM251+ghrelin, ghrelin vs. BAPTA+ghrelin or ghrelin vs. THL+ghrelin groups.
doi:10.1371/journal.pone.0001797.g003
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ical roles for AEA and 2-AG [25]. The effects of ghrelin seem to be
mediated predominantly by 2-AG as this has been the endocan-
nabinoid affected predominantly by ghrelin and our electrophys-
iology data with a 2-AG synthesis inhibitor THL also supports the
2-AG mediation.
The positive feed-back between CB1 receptor and endocanna-
binoid synthesis suggested by these data could explain the lack of
effect of ghrelin in the CB1-KO. Di Marzo et al. previously
showed that there is no difference in hypothalamic cannabinoid
levels between WT and CB1-KO mice [26] and our data
correspond to these findings. We postulate that in WT mice
ghrelin would increase endocannabinoid synthesis, whose levels
are then further amplified by CB1 stimulation, thus leading to
further endocannabinoid biosynthesis. In this way, the presence of
both ghrelin and CB1 receptors would be necessary. The effect of
ghrelin on endocannabinoid synthesis could also be an indirect
one through stimulation of NPY. Similarly to ghrelin, the
orexigenic effect of NPY is abolished by rimonabant administra-
tion and is totally lost in CB1-KO mice [27]. Interestingly, CB1
activation stimulates NPY release [28] therefore a positive feed-
back loop between endocannabinoids and ghrelin-induced NPY
would partly explain the lack of effect in CB1-KO animals.
Conversely, tonic CB1 receptor stimulation alone, without
concomitant ghrelin receptor stimulation, necessary to trigger
both NPY and endocannabinoid synthesis, might not be sufficient
to increase sufficiently the endogenous 2-AG levels, and this might
explain why CB1-KO mice do not exhibit lower endocannabinoid
levels in the hypothalamus.
In this study, we show that the AMPK-stimulating effect of
cannabinoids is also CB1-dependent as it can be blocked by
rimonabant and it is absent in CB1-KO animals. These data
suggest that the CB1-dependent effects of ghrelin on AMPK
activity and appetite are related. The lack of an orexigenic effect of
ghrelin in CB1-KO animals could contribute to their lean
phenotype.
Since in the hypothalamus ghrelin preferentially stimulated the
synthesis of 2-AG, the endocannabinoid that primarily acts in the
excitatory synapses [29], we have studied the influence of ghrelin
on the excitatory input of parvocellular neurons in the PVN. We
observed that ghrelin inhibits the excitatory input on PVN
neurons and this effect is blocked by the co-administration of the
DAG lipase inhibitor, THL or CB1 antagonist, AM251,
suggesting that 2-AG synthesis and functional CB1 is required
for ghrelin to result in this effect. As we have hypothesized that
endocannabinoid synthesis in the recorded PVN neurons
themselves may play an important role in the effect of ghrelin,
and as endocannabinoid synthesis is calcium dependent, we
blocked intracellular calcium by using BAPTA in the recording
electrode. Extracellular ghrelin treatment together with the
intracellular BAPTA administration failed to inhibit the excitatory
input to the postsynaptic neurons of the PVN. This finding
suggests that the blockade of endocannabinoid synthesis by
BAPTA in the postsynaptic cell itself results in blockade of
endocannabinoid release and subsequent lack of stimulation on
the presynaptic CB1, leading to a loss of inhibition of the
excitatory glutamate release from the presynaptic terminal. An
outline of the suggested pathway is shown on Fig. 4. Further
studies are needed to determine whether similar interaction of
ghrelin and cannabinoid signaling exists in other ghrelin sensitive
hypothalamic regions.
In conclusion, the effects of ghrelin investigated in this paper
require an increased release of endocannabinoids, acting through
CB1, to stimulate AMPK and appetite. The hypothalamic
neurophysiological effects of ghrelin also require the presence of
CB1. Taken together, our data indicate that the endogenous
cannabinoid system is necessary for the mediation of the
orexigenic and central AMPK-stimulatory effects of ghrelin.
Materials and Methods
Animals
The experimental CB1-KO and WT mice were derived from a
genotyped stock obtained from IRIBHN, Universite´ Libre de
Bruxelles [30], and were bred at the Institute of Experimental
Medicine (IEM), Budapest. The parent (Belgian) stock was
generated from heterozygotes bred for 14 generations on a CD1
(Charles River, France) outbred background, with selection for the
mutant CB1 gene at each generation. Adult male WT (n = 6–8)
and age-matched CB1-KO littermates (n = 6) weighing 30–35g,
were used in the in vivo experiments. For electrophysiology studies,
3065day old CD1 WT mice were used. The animals were housed
under standard environmental conditions (light between 0600–
1800 h, temperature 2261uC, rodent chow and water ad libitum).
All experimental protocols were reviewed and approved by the
Animal Welfare Committee at the IEM.
In the first set of experiments, WT and CB1-KO mice were
injected intraperitoneally (ip) with 500 mg/kg THC (Tocris,
Avonmouth, UK) and 500 mg/kg rat ghrelin (kind donation of
Prof. Kojima, Japan) in a volume of 100 ml [31]. In the second set
of experiments, WT mice were injected ip with 3 mg/kg
rimonabant (SR141716; Sanofi-Aventis, Paris, France) or vehicle
and 10 min later, with 500 mg/kg ghrelin or vehicle. One hour
after the treatment, while no food was provided, the animals of
both experiments were decapitated. Tissue samples were imme-
Figure 4. Schematic drawing illustrates the proposed model of
ghrelin’s action in the parvocellular neurons of the PVN.
Binding of ghrelin to its receptor (growth hormone secretagogue
receptor 1a, GHS-R1a) on the surface of parvocellular neurons results in
an increase of intracellular Ca2+ levels due to mobilization of Ca2+ from
intracellular stores and opening Ca2+ channels. The increased intracel-
lular Ca2+ level activates the 2-AG synthesizing enzyme diacylglycerol
lipase-a (DAGL), directly or through activation of protein kinase C (PKC),
resulting in an increased 2-AG synthesis and release into the
extracellular space. The increased activation of presynaptic CB1 then
inhibits the release of the excitatory neurotransmitter glutamate (Glu)
from the axons innervating the PVN neurons. Intracellular administra-
tion of the Ca2+-chelator BAPTA blocks this cascade by preventing the
increase of intracellular Ca2+ level, whereas extracellularly-given THL
blocks the 2-AG synthesis and AM251 blocks the cascade at the level of
CB1.
doi:10.1371/journal.pone.0001797.g004
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diately frozen on dry ice and were stored at 280uC until assay.
Hypothalami from the second experiment were processed for
measurement of endogenous cannabinoid content. All injections
were performed between 0900 h and 1200 h.
In a third experiment, WT and CB1-KO mice were implanted
with an intracerebroventricular (icv) cannula [32]. WT and CB1-
KO mice were implanted with 25-gauge stainless steel guide
cannula (Small Parts Inc., Miami Lakes, FL) into the lateral
cerebral ventricle under stereotactic control (coordinates from
Bregma anteroventral 20.2; lateral 1.0; dorsoventral 2.0) through
a burr hole in the skull [32]. The cannula was secured to the skull
with ‘Crazy Glue’ (Electron Microscopy Sciences, Fort Washing-
ton, PA) and dental cement, and temporarily occluded with a
dummy cannula. Bacitracin ointment was applied to the interface
of the cement and the skin. Animals were weighed daily and those
showing signs of illness or weight loss were removed from the study
and euthanized. One week after icv cannulation, both WT and
CB1-KO mice were divided into two groups and received either
vehicle or 1 mg of ghrelin icv in 4 ml aCSF between 0900h and
1000h in the light phase: food intake was measured at 2 h. The
mice had free access to food before and during the experiment.
AMPK activity assay
The kinase assay for AMPK activity has been previously described
[8,33]. Briefly, hypothalami of mice were weighed and homogenized
with Precellys 24 using CK14 tubes containing ceramic beads
(Stretton Scientific, Stretton, UK) at 6000rpm for 1 cycle of 20 sec in
lysis buffer containing 50 mM Tris-HCl, 50 mM NaF, 5 mM Na
pyrophosphate, 1 mM EDTA, 250 mM sucrose, 1% Triton X-100,
1 mM DTT, 1mM benzamidine, 0.1 mM phenylmethane sulfonyl
fluoride, 5 mg/ml soybean trypsin inhibitor, and the tissue protein
content was determined using BCA assay (Pierce, Rockford, USA).
AMPK was immunoprecipitated with an equal mixture of a1AMPK
and a2AMPK antibodies [33] and AMPK activity was determined
by the entity of phosphorylation of SAMS (Pepceuticals Ltd.,
Nottingham, UK), a synthetic peptide substrate of AMPK.
Endocannabinoid content measurement
Following homogenization as above chloroform extraction was
performed and samples dried under nitrogen. An extracted blank
containing the d4-anandamide, but no tissue, was included each time
to control if any apparent cannabinoids or other contaminants were
present during the extraction procedure. Tissue levels of ananda-
mide, 2-AG and 1-AG were quantified by liquid chromatography/
in-line mass spectrophotometry, as previously described [18,34]. The
amount of anandamide, 2-AG and 1-AG in the samples was
determined by using inverse linear regression of standard curves.
Values were calculated as pmol or fmol per mg of wet tissue.
Whole-cell clamp experiments
WT mice were killed by cervical dislocation and were
decapitated. The brain was removed in less than 1 min, and then
immersed in ice cold artificial cerebrospinal fluid (aCSF; NaCl
140 mM, KCl 3 mM, MgSO4 1.3 mM, NaH2PO4 1.4 mM,
CaCl2 2.4 mM, glucose 11 mM, HEPES 5 mM, pH 7.25 with
NaOH) bubbled with O2. Hypothalamic blocks were dissected
from the mouse brains and 300 mm thick slices containing the
PVN were sectioned with a VT-1000S vibratome (Leica GmBH,
Germany) using a sapphire knife (Delaware Diamond Knives Inc.,
Wilmington, DE) in ice-cold oxygenated aCSF. The slices were
bisected along the third ventricle and equilibrated in aCSF
saturated with O2 at room temperature for 1.5 h. In order to
record postsynaptic currents in the neurons, the equilibrated hemi-
slices were placed in an immersion-type recording chamber. The
brain slices were oxygenated, during recording at RT, by bubbling
the aCSF with O2 gas during recording at room temperature. The
cells were voltage clamped at room temperature using a whole-cell
clamp configuration. The instruments used for electrophysiology
were as follows: Axopatch 200B patch clamp amplifier, Digidata-
1322A data acquisition system and pCLAMP 9.2 software (Axon
Instruments-Molecular Devices Co., Sunnyvale, CA). The head-
stage of the amplifier was fitted to a MHW-3 hydraulic
micromanipulator (Narishige Co., Japan). The cells were visual-
ized by a BX51WI upright microscope (Olympus Co. Japan)
equipped with infrared-DIC optics and a Cohu 4912 CCD
camera (Cohu Inc. San Diego, CA) driven by a Scion Image for
Windows Beta 4.0.2 software (Scion Co., Frederick, MD). The
microscope and the micromanipulator were fitted to an S’Table
antivibration table equipped with a Petra platform (Supertech Co.,
Hungary-Switzerland). The patch electrodes (OD = 1.5mm, thin
wall, Garner Co., U.S.A.) were pulled with a Flaming-Brown P-97
horizontal puller (Sutter Instrument Co., Novato, California,
U.S.A.) and polished with an MF-830 microforge (Narishige). The
resistance of the patch electrodes was 2–3 MV.
The intracellular pipette solution used for electrophysiological
recording contained HEPES 10 mM, K-gluconate 120 mM, KCl
10 mM, NaCl 1 mM, MgCl2 1 mM, EGTA 1 mM, Mg-ATP
2 mM, Na-GTP 0.3 mM, pH 7.25 with KOH, osmolarity was set
to 290–295 mOsm using D-sorbitol. In order to block intracellular
calcium-dependent signal transduction pathways, intracellular
calcium was chelated by substituting EGTA with 10 mM BAPTA
(1,2-Bis(2-aminophenoxy)ethane-N,N,N9,N9-tetraacetic acid) in the
intracellular pipette solution. When BAPTA was used in the
intracellular solution, we waited 15 min after establishing a stable
whole-cell clamp configuration in order to equilibrate the
intracellular matrix and the electrode solution containing BAPTA.
The holding potential was 270 mV. Pipette offset potential, series
resistance and capacitance were compensated before recording.
Only cells with low leakage and stable baseline were used for
electrophysiological measurements. The cells requiring any leak
subtraction were omitted. The PVN parvocellular cells were
identified in the acute brain slices by their apparent topographic
location in the PVN. After establishing a stable whole-cell clamp
configuration the cells were identified as neurons by evoking action
potential by injecting +10pA current with 210pA prepulse in
current clamp mode. In order to block voltage sensitive Na-
channels and inhibitory postsynaptic currents (IPSCs) 1 mM
tetrodotoxin (TTX, Tocris) and 100 mM picrotoxin (Sigma) were
added to the aCSF 10 min before the start of recording of
excitatory postsynaptic currents (mEPSCs). When the CB1-
antagonist AM251 (1 mM, Tocris) or the DAG lipase inhibitor
THL (tetrahydrolipstatin, 5 mM, Sigma) were used, they were
added to the aCSF containing TTX and picrotoxin. In order to
determine the effect of ghrelin, first a control measurement of the
mEPSCs was carried out in a neuron. Then ghrelin (100 nM) was
added to the aCSF and 15min later the mEPSCs were recorded
again. Each recording lasted 258sec. In order to block excitatory
inputs of the neurons examined, the glutamate receptor inhibitor
kynurenic acid (5 mM, Sigma) was applied in the extracellular
solution after recording control EPSCs.
In order to demonstrate the effect of ghrelin, four parameters of
the mEPSCs were analyzed: amplitude of the pulses; the
interevent interval representing the period between the peaks
of the current and the previous event; the instantaneous
frequency representing event frequency at the rate of the current
and the previous event; and the event frequency representing
event frequency over the entire data set (i.e. over the 258sec
recording).
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Statistical analysis
Data were analyzed using the Student’s t-test, the ANOVA
followed by the Newman-Keuls test or the Kruskal-Wallis test
followed by Conover-Inman comparison, as appropriate (Graph-
Pad Software Inc., San Diego, CA). Electrophysiological record-
ings were carried out on at least 8 cells for each experimental
group. Baseline correction of the mEPSC recordings was carried
out using the Corrector software (L. Tatai, G. Lo˝csei and B.
Wittner, KOKI, Budapest). Event detection was performed using
the Clampfit module of the PClamp 9.2 software (Molecular
Devices, Union City, CA). Significance was taken at P,0.05. The
data are expressed as mean6standard error (SEM), n = 6–8 in
each treatment group, except where differently specified.
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